A Study of OPC-262 in Patients With Type 2 Diabetes

Phase 3 Completed 100 enrolled Kyowa Kirin, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.

Timeline

Start: 2009-11
Primary completion: 2011-07
Completion: 2011-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OPC-262	Unknown	5 mg	Oral

A Study of OPC-262 in Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications